A partner for translatable preclinical data to clinical trials
Need a research partner to customize or develop a new model or method? MD Biosciences has experience in developing new methods and models to suit sponsors needs. Currently, the industry uses preclinical models that are available to assess activity of a particular compound prior to going to clinic. However, this approach leads to > 80% failure rate as the compound begins efficacy in human clinical trials. This has brought a burden on the pharma industry both for R&D budgets and lack of novel therapies brought to market.
Our goal is to bring modified or newly developed models that will reduce this burden, equipping drug developers with more clinically relevant preclinical data. We want to understand what the clinician would expect from an active compound in a particular therapeutic area. From this understanding, our goal is to work backwards to develop and provide the proper preclinical models that will break the preclinical/clinical barrier.
From custom methods to drug delivery to completely new model systems, MD Biosciences can assist in developing the project that will answer the question you need to address. Contact a scientist to discuss a custom development project.